Ildong Pharmaceutical Co., Ltd. (KRX:249420)
South Korea flag South Korea · Delayed Price · Currency is KRW
30,650
-450 (-1.45%)
At close: Nov 21, 2025

Ildong Pharmaceutical Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2019
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2019
Operating Revenue
575,656614,941600,758637,714560,132561,845
Upgrade
Other Revenue
---0--0-
Upgrade
575,656614,941600,758637,714560,132561,845
Upgrade
Revenue Growth (YoY)
-5.67%2.36%-5.79%13.85%-0.30%8.58%
Upgrade
Cost of Revenue
352,760381,659387,093401,627340,958323,674
Upgrade
Gross Profit
222,896233,282213,665236,088219,174238,171
Upgrade
Selling, General & Admin
160,700167,539165,116190,252171,296164,598
Upgrade
Research & Development
35,31146,26895,018109,89596,52460,181
Upgrade
Other Operating Expenses
1,3301,2621,2163,8141,0871,454
Upgrade
Operating Expenses
204,149221,851267,082309,754273,586232,642
Upgrade
Operating Income
18,74711,431-53,418-73,666-54,4125,529
Upgrade
Interest Expense
-13,984-15,938-14,725-9,788-10,556-4,669
Upgrade
Interest & Investment Income
1,1481,1261,0931,552569.37260.18
Upgrade
Earnings From Equity Investments
147.75-273.49-0.36-0.54-1.67-
Upgrade
Currency Exchange Gain (Loss)
-655.55-1,016-748.46-475.09168.49-771.47
Upgrade
Other Non Operating Income (Expenses)
18,7526,790-24,556-20,485-75,4581,049
Upgrade
EBT Excluding Unusual Items
24,1552,119-92,354-102,862-139,6901,397
Upgrade
Gain (Loss) on Sale of Investments
9,2821,955439.722,325-862.82-5,222
Upgrade
Gain (Loss) on Sale of Assets
-6,124-4,9081,133-282.22-101.532,029
Upgrade
Asset Writedown
-5,757-9,857-3,492-19,004-550.27-7,928
Upgrade
Pretax Income
21,557-10,692-94,273-119,823-141,205-9,724
Upgrade
Income Tax Expense
606.451,710-13,31222,346-40,2373,295
Upgrade
Earnings From Continuing Operations
20,951-12,402-80,961-142,170-100,968-13,019
Upgrade
Minority Interest in Earnings
6,9727,8252,033584.61,263-
Upgrade
Net Income
27,923-4,576-78,928-141,585-99,705-13,019
Upgrade
Net Income to Common
27,923-4,576-78,928-141,585-99,705-13,019
Upgrade
Shares Outstanding (Basic)
282827262424
Upgrade
Shares Outstanding (Diluted)
282827262424
Upgrade
Shares Change (YoY)
2.14%3.34%2.61%10.76%-0.00%-0.02%
Upgrade
EPS (Basic)
980.97-163.83-2920.01-5374.53-4191.88-547.34
Upgrade
EPS (Diluted)
980.97-163.83-2920.01-5379.82-4192.00-547.34
Upgrade
Free Cash Flow
6,67517,614-49,817-65,413-25,9925,014
Upgrade
Free Cash Flow Per Share
234.52630.60-1843.01-2483.08-1092.76210.79
Upgrade
Gross Margin
38.72%37.94%35.57%37.02%39.13%42.39%
Upgrade
Operating Margin
3.26%1.86%-8.89%-11.55%-9.71%0.98%
Upgrade
Profit Margin
4.85%-0.74%-13.14%-22.20%-17.80%-2.32%
Upgrade
Free Cash Flow Margin
1.16%2.86%-8.29%-10.26%-4.64%0.89%
Upgrade
EBITDA
42,77137,366-25,099-44,121-25,10133,192
Upgrade
EBITDA Margin
7.43%6.08%-4.18%-6.92%-4.48%5.91%
Upgrade
D&A For EBITDA
24,02325,93528,31929,54529,31127,663
Upgrade
EBIT
18,74711,431-53,418-73,666-54,4125,529
Upgrade
EBIT Margin
3.26%1.86%-8.89%-11.55%-9.71%0.98%
Upgrade
Effective Tax Rate
2.81%-----
Upgrade
Advertising Expenses
-32,05325,84637,39235,75735,659
Upgrade
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.